摘要
目的系统评价异甘草酸镁治疗重型肝炎肝衰竭的疗效和安全性。方法检索PubMed、Cochrane图书馆、Embase、万方数据库、维普数据库、中国生物医学文献数据库和CNKI等数据库从1990年1月至2016年7月公开发表的文献。纳入异甘草酸镁与其他甘草酸制剂治疗重型肝炎肝衰竭的随机对照研究。由2名研究者独立筛查文献、提取资料并进行质量评价,采用RevMan 5.2软件进行Meta分析。结果经筛选共纳入6项随机对照试验,合计565例患者。Meta分析结果显示:试验组患者丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、凝血酶原时间(PT)及不良反应发生率均显著低于对照组(P均<0.05)。结论异甘草酸镁可显著降低重型肝炎肝衰竭患者的ALT、TBil及PT水平,不良反应的发生率显著低于其他甘草酸制剂。
Objective To systematically evaluate the efficacy and safety of magnesium isoglycyrrhizinate in treatment of severe hepatitis patients with liver failure. Methods The relevant randomized controlled trials were searched throughout PubMed, Cochrane Library, Embase, WanFang database, Chinese VIP database,CBMdisc database and CNKI database from January 1990 to July 2016. Trials comparing the efficacy of magnesium isoglycyrrhizinate versus other glycyrrhizin in severe hepatitis patients with liver failure were included. The methodological quality and data extraction of included trials were completed by two independent investigators. Meta-analysis was performed with Review Manager Software 5.2. Results Six eligible trials including 565 patients were included and assessed. According to the results of meta-analysis,magnesium isoglycyrrhizinate was remarkably more effective than other glycyrrhizin in terms of alanine transaminase （ALT）, total bilirubin （TBil）, prothrombin time （PT） and the incidence rate of adverse reaction （P〈0.05）. Conclusions Magnesium isoglycyrrhizinate is more effective and safe in decreasing the levels of ALT, TBil, PT and the incidence rate of adverse reaction in patients with severe hepatitis liver failure.
出处
《中国肝脏病杂志（电子版）》
CAS
2017年第1期15-19,共5页
Chinese Journal of Liver Diseases：Electronic Version
基金
宜宾市科技计划项目(2015SF031)
